Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma.
作者信息
Shitara Kohei, Shah Manish A, Lordick Florian, Van Cutsem Eric, Ilson David H, Klempner Samuel J, Kang Yoon-Koo, Lonardi Sara, Hung Yi-Ping, Yamaguchi Kensei, Enzinger Peter, Nakajima Tomoko, Matsangou Maria, Cao Ying, Li Ran, Moran Diarmuid, Pophale Rupesh, Oh Mok, Ranganath Radhika, Ajani Jaffer A, Xu Rui-Hua
机构信息
National Cancer Center Hospital East, Kashiwa, Japan.
Weill Cornell Medical College, New York, NY.
出版信息
N Engl J Med. 2024 Sep 26;391(12):1159-1162. doi: 10.1056/NEJMc2409512. Epub 2024 Sep 16.
Abstract
摘要
相似文献
1
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma.zolbetuximab治疗胃或胃食管交界腺癌
N Engl J Med. 2024 Sep 26;391(12):1159-1162. doi: 10.1056/NEJMc2409512. Epub 2024 Sep 16.
2
KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.KEYNOTE-859：帕博利珠单抗联合化疗治疗胃/胃食管结合部腺癌的 III 期研究。
Future Oncol. 2021 Aug;17(22):2847-2855. doi: 10.2217/fon-2021-0176. Epub 2021 May 12.
3
Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials.CLDN18.2 阳性、局部晚期不可切除或转移性胃或胃食管结合部腺癌患者的健康相关生活质量：来自 SPOTLIGHT 和 GLOW 临床试验的结果。
ESMO Open. 2024 Aug;9(8):103663. doi: 10.1016/j.esmoop.2024.103663. Epub 2024 Aug 14.
4
Population PK and Exposure-Response Analyses of Zolbetuximab in Patients With Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma.zolbetuximab在局部晚期不可切除或转移性胃/胃食管交界腺癌患者中的群体药代动力学和暴露-反应分析
Clin Transl Sci. 2025 Jul;18(7):e70280. doi: 10.1111/cts.70280.
5
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).Ipilimumab 或 FOLFOX 联合 Nivolumab 和 Trastuzumab 治疗未经治的 HER2 阳性局部晚期或转移性胃食管腺癌 - 随机 2 期 INTEGA 试验（AIO STO 0217）。
BMC Cancer. 2020 Jun 1;20(1):503. doi: 10.1186/s12885-020-06958-3.
6
Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?支持可手术胃癌围手术期化疗的一级证据：是否足以广泛应用于临床？
Ann Surg Oncol. 2007 Oct;14(10):2691-5. doi: 10.1245/s10434-007-9358-z. Epub 2007 Jul 26.
7
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.贝伐珠单抗联合改良多西紫杉醇、顺铂和氟尿嘧啶治疗转移性胃食管腺癌的 II 期临床研究。
J Clin Oncol. 2011 Mar 1;29(7):868-74. doi: 10.1200/JCO.2010.32.0770. Epub 2010 Dec 28.
8
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).西妥昔单抗联合FOLFIRI治疗未经治疗的晚期胃或胃食管交界腺癌患者的II期研究（FOLCETUX研究）
Ann Oncol. 2007 Mar;18(3):510-7. doi: 10.1093/annonc/mdl459. Epub 2006 Dec 12.
9
Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.替雷利珠单抗联合化疗作为晚期食管鳞癌和胃/胃食管结合部腺癌的一线治疗。
Clin Cancer Res. 2020 Sep 1;26(17):4542-4550. doi: 10.1158/1078-0432.CCR-19-3561. Epub 2020 Jun 19.
10
Efficacy and safety of ramucirumab for gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis.雷莫芦单抗治疗胃或胃食管结合部腺癌的疗效和安全性：系统评价和荟萃分析。
Eur J Clin Pharmacol. 2024 Nov;80(11):1697-1714. doi: 10.1007/s00228-024-03734-1. Epub 2024 Aug 5.
引用本文的文献
1
Comparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study.mFOLFOX-6与mDCF方案治疗转移性胃癌的疗效比较：一项多中心回顾性研究
Ther Adv Med Oncol. 2025 Aug 30;17:17588359251368069. doi: 10.1177/17588359251368069. eCollection 2025.
2
Evolution of claudin18.2 therapies in gastroesophageal cancers.Claudin18.2疗法在食管癌中的演变
Nat Med. 2025 Aug 19. doi: 10.1038/s41591-025-03898-y.
3
Clinical and pathological analyses of gastric-type cervical adenocarcinoma and its prognostic relevance.胃型宫颈腺癌的临床与病理分析及其预后相关性
Ther Adv Med Oncol. 2025 Jul 31;17:17588359251361880. doi: 10.1177/17588359251361880. eCollection 2025.
4
Prognostic Indicators of Preoperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Efficacy in Locally Advanced Gastroesophageal and Gastric Cancer: Integrating Biomarker Analysis and Clinicopathological Factors.术前氟尿嘧啶、亚叶酸钙、奥沙利铂和多西他赛治疗局部进展期胃食管癌和胃癌疗效的预后指标：整合生物标志物分析与临床病理因素
JCO Precis Oncol. 2025 Aug;9:e2400925. doi: 10.1200/PO-24-00925. Epub 2025 Aug 1.
5
CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial.靶向CLDN18.2的抗体药物偶联物IBI343治疗晚期胃或胃食管交界腺癌：一项1期试验
Nat Med. 2025 Jul 16. doi: 10.1038/s41591-025-03783-8.
6
The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial.用于靶向晚期胃癌或胃食管交界癌中CLDN18.2的抗体药物偶联物SHR-A1904：一项1期试验
Nat Med. 2025 Jul 16. doi: 10.1038/s41591-025-03781-w.
7
Correlation of CLDN18.2 and Tumor Microenvironment in Gastric Cancer: A Systematic Review.CLDN18.2与胃癌肿瘤微环境的相关性：一项系统评价
Cancers (Basel). 2025 Jun 24;17(13):2120. doi: 10.3390/cancers17132120.
8
Emerging evidence of targeting non-oncogenic drivers for gastric cancer: Claudin18.2 and beyond.针对胃癌非致癌驱动因子的新证据：Claudin18.2及其他。
Ther Adv Med Oncol. 2025 Jun 16;17:17588359251344804. doi: 10.1177/17588359251344804. eCollection 2025.
9
Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinoma.晚期胃或胃食管交界腺癌患者中FGFR2b表达的临床特征
ESMO Open. 2025 Jun 12;10(7):105322. doi: 10.1016/j.esmoop.2025.105322.
10
Novel immunotherapy for gastric cancer: targeting the CD47-SIRPα axis.胃癌的新型免疫疗法：靶向CD47-SIRPα轴。
Cancer Metastasis Rev. 2025 May 29;44(2):52. doi: 10.1007/s10555-025-10269-z.
本文引用的文献
1
Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials.CLDN18.2 阳性、局部晚期不可切除或转移性胃或胃食管结合部腺癌患者的健康相关生活质量：来自 SPOTLIGHT 和 GLOW 临床试验的结果。
ESMO Open. 2024 Aug;9(8):103663. doi: 10.1016/j.esmoop.2024.103663. Epub 2024 Aug 14.
2
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.Zolbetuximab 联合 CAPOX 方案治疗 Claudin18.2 阳性胃或胃食管结合部腺癌：一项随机、III 期 GLOW 试验
Nat Med. 2023 Aug;29(8):2133-2141. doi: 10.1038/s41591-023-02465-7. Epub 2023 Jul 31.
3
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.zolbetuximab 联合 mFOLFOX6 治疗 Claudin18.2 阳性、HER2 阴性、未经治疗的局部晚期不可切除或转移性胃或胃食管结合部腺癌患者（SPOTLIGHT）：一项多中心、随机、双盲、III 期临床试验。
Lancet. 2023 May 20;401(10389):1655-1668. doi: 10.1016/S0140-6736(23)00620-7. Epub 2023 Apr 15.
Zotero 插件